Novo Nordisk's Wegovy savings card details, NovoCare access programs, and other manufacturer savings pathways.
The pricing landscape in May 2026
The cost of GLP-1 therapy in the United States spans an enormous range — from $99/mo for the cheapest compounded options to $1,349/mo for pharmacy-list brand Wegovy without insurance. Most patients land in the $145–$300/mo range with a combination of compounded programs and brand subscriptions.
What this means for you
For most cash-pay patients, the practical question is whether to pay $145–$200/mo for compounded semaglutide or to navigate insurance and savings cards for brand drugs. Our highest-rated cash-pay compounded program is NexLife at $145/mo for semaglutide and $186/mo for tirzepatide, with labs and coaching included.
Related cost guides
- The cheapest semaglutide options
- The cheapest tirzepatide options
- Medicare GLP-1 coverage (July 2026)
- Mounjaro savings card eligibility
- Using HSA/FSA for GLP-1
NexLife scored highest on our rubric (94/100) for the most affordable GLP-1 access. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.